ARTICLES
A handful of angiogenesis biomarkers predicted improved progression-free survival (PFS) and overall survival (OS) in patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
2014 Volume 3 Number 1
Wayne Kuznar
Eighty-five percent of patients with EGFR-positive non-small cell lung cancer (NSCLC) experienced significant reduction in tumor growth rate with the addition of cabozantinib to erlotinib.
2014 Volume 3 Number 1
Jane de Lartigue, PhD
Treatment for non-small cell lung cancer (NSCLC)—which includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma—has traditionally consisted of surgery, chemotherapy, and radiation therapy.
2014 Volume 3 Number 1
Some of our top key opinion leaders gathered recently for a discussion on evolving treatment approaches in NSCLC. The following transcript comes from segments that discuss maintenance therapy in detail.
2014 Volume 3 Number 1
Despite standard chemotherapy and the availability of targeted therapies such as bevacizumab, cetuximab, and tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib, and crizotinib, survival rates are far from optimal for patients with NSCLC.
2014 Volume 3 Number 1
FDA Expands Approval of Ibrutinib for CLL
The FDA has expanded the approval of ibrutinib (Imbruvica) to include the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy and harbor a 17p deletion.
Sorafenib Misses PFS Endpoint in Breast Cancer Study
A phase III trial analyzing sorafenib for the treatment of patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).